Recent advances in understanding steatotic liver disease have revealed overlapping biological processes that may contribute to non-alcoholic fatty liver disease (NAFLD). Join us in this podcast series where your colleagues will take you on a journey to better understand the cardiometabolic basis for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), which has long been recognized as “the hepatic manifestation of the metabolic syndrome.” In this series, we will explore MASH, including epidemiology, pathophysiology, comorbidities, patients at risk, and HCP perspectives on the patient journey. This series is tailored specifically for healthcare professionals seeking deeper insights into MASH.
Expose MASH [Formerly NASH] is tailored for healthcare professionals seeking to stay at the forefront of liver disease knowledge. This podcast is sponsored by Novo Nordisk and is intended for U.S. clinicians. This podcast is not to be used as medical advice.
All content for Expose MASH [Formerly NASH] is the property of Novo Nordisk and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Recent advances in understanding steatotic liver disease have revealed overlapping biological processes that may contribute to non-alcoholic fatty liver disease (NAFLD). Join us in this podcast series where your colleagues will take you on a journey to better understand the cardiometabolic basis for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), which has long been recognized as “the hepatic manifestation of the metabolic syndrome.” In this series, we will explore MASH, including epidemiology, pathophysiology, comorbidities, patients at risk, and HCP perspectives on the patient journey. This series is tailored specifically for healthcare professionals seeking deeper insights into MASH.
Expose MASH [Formerly NASH] is tailored for healthcare professionals seeking to stay at the forefront of liver disease knowledge. This podcast is sponsored by Novo Nordisk and is intended for U.S. clinicians. This podcast is not to be used as medical advice.
Join us in this episode of Expose MASH, as our experts delve into a discussion focused on the importance of identifying and referring patients at risk for MASH with clinically significant fibrosis (≥F2). Our experts will discuss the liver specialist perspective on the urgency for specialty referral of appropriate patients, including the increased morbidity and mortality associated with advancing liver fibrosis. They will also provide an overview of the importance of multidisciplinary collaboration and highlight the key role of primary care providers and endocrinologists as the front line for identification of patients before MASH progresses to clinically significant fibrosis.
In this episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we will share insights on the current MASH guidelines. The adoption of the new MASH nomenclature, with the inclusion of cardiometabolic risk factors into its formal definition, will be briefly discussed before examining the different clinical guidelines that are available. We will identify shared recommendations and key points of difference for the screening and management of this complex disease. We will then look to the future to discuss how emerging data may inform future guidelines and help optimize clinical practice. This episode is brought to you by Novo Nordisk Inc.
In this sixth episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we share insight on primary fibrosis risk assessment using the FIB-4 index in patients with MASH (metabolic dysfunction-associated steatohepatitis). Our experts explain the importance of noninvasive tests as a useful tool to identify patients at high risk for MASH. Futhermore, they discuss the relevance of using the FIB-4 test in order to facilitate timely intervention for these at-risk patients. This episode is brought to you by Novo Nordisk Inc.
Join us on this episode of Expose MASH—intended for US healthcare professionals only—as our experts share their approaches to educating patients about MASH and overall liver health. The conversation will examine the importance of educating patients on the disease and how effectively communicating with patients can help raise awareness of MASH, increase screening, and improve diagnosis rates and management of this condition. Our experts will discuss best practices for educating patients on key aspects of MASLD and MASH, including understanding the disease, its prevalence, and progression. Furthermore, the conversation will explore the importance of patient and HCP conversations to improve early risk identification and impact overall liver health. This episode is brought to you by Novo Nordisk Inc.
In this episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we take a closer look at the pathophysiology of MASH (metabolic dysfunction-associated steatohepatitis) to understand which patients are at high risk for MASH. Join us as we discuss the systemic dysfunction at the root of MASH and other metabolic disorders, exploring how shared disease pathways can help inform patient identification, screening, and holistic patient management. This episode is brought to you by Novo Nordisk Inc.
Join us in the third episode of Expose MASH [formerly NASH], as our experts turn their attention to the heart of the matter: the patients. We will explore the MASH patient journey, from initial symptoms to living with MASH. Our conversation will focus on the urgency for improved identification of at risk patients, guidelines for testing, and effective disease management. Our experts will discuss risk assessment and how to manage patient’s comorbidities. Furthermore, we will explore the importance of coordinated care between HCPs and liver specialists to provide a holistic approach to MASH management.
This second episode of Expose MASH [formerly NASH] will deep dive into how metabolic syndrome can contribute to liver disease. Our experts will explore why MASH is a cardiometabolic disorder and how this new perspective on liver disease can lead to improvements in identifying at-risk patients and managing cardiometabolic comorbidities. Join us as we navigate through this episode, offering a deeper understanding of the intersection between cardiometabolic dysfunction and liver health.
In this first episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we embark on a journey into the world of MASH (metabolic dysfunction-associated steatohepatitis). Our experts will explain what MASH is and share their insights on the new MASH name, offering a glimpse into how it may help to reshape the landscape of liver disease screening, diagnosis, and management. Join us as we explore the MASH disease state and lay the foundation for future episodes focused on specific aspects of MASH screening and management.
Recent advances in understanding steatotic liver disease have revealed overlapping biological processes that may contribute to non-alcoholic fatty liver disease (NAFLD). Join us in this podcast series where your colleagues will take you on a journey to better understand the cardiometabolic basis for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), which has long been recognized as “the hepatic manifestation of the metabolic syndrome.” In this series, we will explore MASH, including epidemiology, pathophysiology, comorbidities, patients at risk, and HCP perspectives on the patient journey. This series is tailored specifically for healthcare professionals seeking deeper insights into MASH.
Expose MASH [Formerly NASH] is tailored for healthcare professionals seeking to stay at the forefront of liver disease knowledge. This podcast is sponsored by Novo Nordisk and is intended for U.S. clinicians. This podcast is not to be used as medical advice.
